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EDITORIAL
Molecular biology: the key to personalised treatment in radiation
oncology?
D G HIRST, BSc, PhD, FBIR, and T ROBSON, MIBIOL, PhD
School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast, BT9 7BL
ABSTRACT.We know considerably more about what makes cells and tissues resistant or
sensitive to radiation than we did 20 years ago. Novel techniques in molecular biology
have made a major contribution to our understanding at the level of signalling
pathways. Before the ‘‘New Biology’’ era, radioresponsiveness was defined in terms of
physiological parameters designated as the five Rs. These are: repair, repopulation,
reassortment, reoxygenation and radiosensitivity. Of these, only the role of hypoxia
proved to be a robust predictive and prognostic marker, but radiotherapy regimens
were nonetheless modified in terms of dose per fraction, fraction size and overall time,
in ways that persist in clinical practice today. The first molecular techniques were
applied to radiobiology about two decades ago and soon revealed the existence of
genes/proteins that respond to and influence the cellular outcome of irradiation. The
subsequent development of screening techniques using microarray technology has
since revealed that a very large number of genes fall into this category. We can now
obtain an adequately robust molecular signature, predicting for a radioresponsive
phenotype using gene expression and proteomic approaches. In parallel with these
developments, functional magnetic resonance imaging (fMRI) and positron emission
tomography (PET) can now detect specific biological molecules such as haemoglobin
and glucose, so revealing a 3D map of tumour blood flow and metabolism. The key to
personalised radiotherapy will be to extend this capability to the proteins of the
molecular signature that determine radiosensitivity.
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Molecular biology developments have, over the past
20 years, provided us with a remarkable array of tech-
niques, enhancing our understanding of how tumour
and normal tissues respond to radiation damage. As
these techniques grow increasingly sophisticated, their
application should, in theory, present opportunities to
improve the effectiveness of radiotherapy.
However, as we look at how radiotherapy is per-
formed today we see a discipline founded on 100 years of
practice-based, empirical development, recently en-
hanced by impressive advances in dose delivery and
image-guided procedures. These developments have
brought us to a point where dose deposition is already
highly tailored, to a tolerance of ,2% for most tissues of
the body, which is much more accurate than any
pharmaceutical agent. Yet, are we really delivering dose
where it needs to go for maximal therapeutic gain?
Basic radiobiology and the five Rs
The interaction of high energy X-ray photons with
tissue leads to the ejection of fast electrons from
molecules (predominantly water), which in turn go on
to generate a wide spectrum of secondary electrons,
photons and free radicals. The most reactive of these
radicals, OH, is capable of creating further radicals of
macromolecules. If these are essential for cellular
function, as in the case of DNA, then cell biology will
be perturbed and this may lead to cell death.
These processes have been known for at least 50 years,
but there is still much to learn about the full spectrum of
damaging species resulting from an incident high-energy
photon. It is also well established that the initial
consequences at the cellular level of free radical forma-
tion can be fundamentally modified by two main
conditions: the oxygen tension and the concentration of
free radical scavengers such as glutathione. How the cell
handles and responds to its accumulated damage then
depends on more complex processes involving DNA
repair and activation of death signalling pathways.
Consequences at the tissue level are more complex still
and their relevance to radiation oncology was initially
explained in terms of the four Rs of Radiobiology: DNA
repair (enzymic), reoxygenation (of previously hypoxic
cells), repopulation (cell proliferation), redistribution (to
phases of the cell cycle with differing radiosensitivity).
Later, it was recognised that sensitivity between cell lines
could also vary for reasons that could not be explained
by the four Rs, so a fifth R, intrinsic radiosensitivity, was
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added [1]. These five concepts could explain in general
terms the variability in cellular and even tissue response,
but in most cases really tell us little about the mechan-
isms regulating the response to radiation exposure at the
molecular level. The more recent application of mole-
cular techniques to this subject has added extra complex-
ity, and this has been comprehensively reviewed [2].
Predictive testing based on traditional
radiobiology
Each of the five Rs is capable of contributing a
substantial dose modifying factor (2–5, though most are
not strictly dose modifying) to the eventual outcome of
radiotherapy. It is therefore logical that an assessment of
these parameters in individual patients could be of
enormous predictive value.
However, this has not proved to be true, with attempts
to develop predictive assays based on measurement of
these five parameters being met with mixed success. But
we should remember that the science underlying the five
Rs was aimed at providing a framework to aid under-
standing of new phenomena in radiation biology rather
than predicting outcomes. Furthermore, the lack of
success may be because there are only small quantitative
differences between many normal tissues and human
tumours, and a large degree of overlap in their
heterogeneity.
Hypoxia
It has been known for many years that hypoxia,
measured using a variety of direct and indirect methods,
correlates strongly with the outcome of all cancer
therapies. This is not just limited to patients receiving
therapies that are known to be oxygen-dependent in
their cytotoxic action, such as radiotherapy [3].
There is now overwhelming evidence the hypoxia
regulates cancer outcome by several mechanisms includ-
ing increasing inflammation, promoting malignant pro-
gression and directly reducing the effectiveness of
therapies [4]. The application of molecular techniques
has greatly enhanced our understanding of how these
phenomena are mediated, particularly the role of the
master regulator HIF-1.
For prostate cancer patients treated with radiotherapy
or surgery only, increased staining for HIF-1 alpha
expression and the key downstream mediator, vascular
endothelial growth factor (VEGF), were significant
predictors of a shorter time to biochemical failure [5].
Furthermore, a 99-gene hypoxia gene signature derived
from head and neck tumours might turn out to be
radiobiologically relevant in terms of stratifying patients
for radiation treatment [6], as would the meta-signature
highlighted by the same group [7].
Cell kinetics
Cell cycle parameters vary widely between individual
human tumours and it is logical to imagine that the
duration of the cell cycle or of its distinct phases should
have some influence on the outcome of radiotherapy.
After all, we know that cells are more sensitive to
radiation in some phases than others and that prolifera-
tion is related to the rate of tumour regrowth during and
after treatment. Few studies have been large enough
individually to give a statistically significant answer.
However, one multivariate analysis of head and neck
cancer patients from 11 different European centres
showed clearly that no cell kinetic parameter could be
relied upon to predict local control [8].
Intrinsic radiosensitivity
It might seem self-evident that the intrinsic radio-
sensitivity of tumour or even normal cells derived from
cancer patients should correlate with the outcome of
treatment. Not only has this been hard to demonstrate,
but different endpoints for DNA damage do not correlate
well with each other [9].
The most extensive studies have involved measure-
ment of the surviving fraction of tumour cells from
cervix cancer patients in vitro after 2 Gy (SF2) [10–12]. A
clear correlation was found, though it required careful
selection of the appropriate cut-off value for SF2 (0.42) to
discriminate clearly between good and poor outcomes. A
similar result was also obtained, though not consistently
in head and neck cancer [13–15].
However, the limitations of these approaches are
probably both technical and biological. Primary cultures
from human tumours are very hard to grow and even
when they do form colonies, the plating efficiencies are
around 1%. This would not matter if tumours contained
uniform cells populations, but the discovery of cancer
stem cells supports the view that the clinical response of
tumours is dominated by a very small, resistant sub-
population of cells that can proliferate indefinitely [16].
The remainder of the tumour cells are largely irrelevant.
Thus, SF2 values are averages across a very large number
of cells and so are not so representative of the resistant
clones that determine cure or relapse. As well as these
difficulties, the SF2 assay has another crucial weakness –
even when a tumour sample does generate colonies, the
result takes up to a month to obtain.
The general acceptance of the importance of the
double strand break as a key DNA lesion determining
cell fate after irradiation has lead to a assessment of its
repair as a surrogate marker of radiation sensitivity (see
Hennequin et al 2009 [16] for review). Results have been
variable: in one study of ten human tumour cell lines,
DNA end-binding complexes (indicative of initiation of
repair) correlated with SF2 in primary fibroblast cultures
and human tumour cell lines [17]. A more definitive
assay may be the scoring of chromosome aberrations and
there is clear evidence from work on human cell lines
that they may predict for cell survival [18, 19].
Functional genomics and molecular responses
to radiation exposure
We now know that exposure to ionising radiation, in
common with other DNA-damaging agents, initiates a
complex series of up and down regulations of genes
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interacting through many pathways. The pioneering
work in this area was carried out more than 20 years
ago by Fornace and colleagues, who showed, using
cDNA library screening, that key genes, GADD45A and
p21(CIP1/WAF1), were up-regulated by ionising radiation
[20, 21]. The pivotal role of the p53 regulator became
apparent around this time and data suggested that
multiple pathways downstream of this master regulator
must be important in the response of cells to ionising
radiation. Key proteins include GADD45, CDKN1A and
MDM2. Initial studies showed that they were induced by
a large dose (20 Gy) of X-rays, but not in all cell lines and
not in a predictable, p53-dependent manner [20].
The advent of microarray technologies provided novel
tools for the identification of changes in gene expression
in response to ionising radiation. The first application of
this technology to radiation response again used large
(20 Gy) doses and allowed the relationships between a
variety of genes, many unknown and many regulated by
p53, to be mapped out [21]. The same group also showed
that microarray analysis could also detect differential
gene expression in blood cells in response to radiation
doses in the clinically relevant therapeutic range of 2 Gy
or less. Many of these genes, which we know are
involved in apoptosis or cell cycle checkpoints, show a
dependency on dose rate [21].
Microarray analysis has also been instrumental in
revealing the mechanisms involved in mediating bystan-
der killing in unirradated cell populations adjacent to
and sharing a common medium with irradiated ones.
This includes evidence for the involvement of connexin
43, a protein with a role in gap junction communication,
and cyclooxygenase [22]. Bystander responses can also
be transmitted via the medium that has supported the
growth of irradiated cells [23]. While no comprehensive
profiling has been carried out p53, p21 MDM2, CDC2,
Cyclin B1 and RAD51 are all significantly modulated in
bystander cells.
Considerable effort has been invested in evaluating the
expression of individual genes and gene products as
markers of biological response to radiotherapy. This
raised expectations that biomarkers would more accu-
rately predict outcome than traditional approaches that
relied on size, dissemination, stage and grade. While
biomarkers for response to chemotherapy are increas-
ingly recognised e.g. HER2/neu in breast cancer (see
Lawrence et al, 2008 [24] for review) their application to
radiotherapy planning is much less advanced. The role
of the cell cycle and DNA repair regulator EGFR in
determining radiosensitivity has been documented in
tumours in several sites (colorectal, brain and head an
neck), but the correlation is not wholly consistent.
Similar associations have been reported for members of
the p53 gene family and genes regulated by p53 [25, 26].
Also, several genes including, cyclin D1, TS, TP, DPD,
and Her-2/neu have been shown, using quantitative RT-
PCR techniques, to be predictors of response, survival,
and recurrence in patients treated with radiochemother-
apy for squamous cell carcinoma of the oesophagus [26].
As the number of genes implicated in response to
radiotherapy increases, several groups have used micro-
array analysis to obtain a global signature indicative of
radioresponsiveness/resistance in colorectal cancer
[27–29]. Several other gene signatures have emerged in
relation to the radioresponse of cervical, breast and head
and neck tumours (reviewed in West et al 2007 [30]) and
more recently in breast cancer [31, 32]). However,
overlap between these gene signatures is minimal, the
statistical significance has been questioned and there are
no large-scale, randomised trials yet published to fully
validate the usefulness of any of these signatures in the
different tumour types. What is needed is a gene
expression model that predicts intrinsic radiosensitivity
and treatment response in a broad spectrum of cancer
patients. A useful approach may be to determine
differential expression of key genes with known roles
in processes that could impact on biological response to
radiation (see Begg 2009 [33] for recent review). An
important step in that direction was taken in a recently
published study [33]. Radiosensitivity was modelled as a
function of gene expression, tissue of origin, ras (mut/
wt), and p53 status (mut/wt) in 48 human rectal, head
and neck and oesophageal cancer cell lines. This group
identified 10 key or ‘‘hub’’ genes involved in pathways
central to the regulation of cell signalling.
We are accustomed to seeing well-defined relation-
ships (e.g. linear quadratic) between radiation dose and
endpoints for cell damage such as cell survival, but it
became clear early on that changes in the expression of
radiation-modulated genes do not generally exhibit these
relatively simple dependencies. For example, a transcrip-
tional response that is exclusive to low doses has been
reported in several studies [35–38].
Gene expression studies such as these have helped to
identify pathways of interest, but we need to be aware
that cellular responses are mediated at the protein level
such that translational regulation, post translational
modification and degradation of proteins must add
additional levels of complexity to the genomic responses
identified by microarrays.
As well as using gene expression as a radiobiological
endpoint. other investigators have used genotyping to
link germ-line single nucleotide polymorphisms (SNPs)
within both normal and tumour tissue, with a view to
assessing normal tissue radiation toxicity and tumour
response [30, 39]. With particular reference to tumour
response, the studies demonstrated that genetic varia-
tions associated with DNA repair and apoptosis appear
to be important. Four large studies are now under way to
fully validate markers for normal tissue radiation toxicity
[40, 43], though large-scale validation of SNPs that might
be useful predictive markers of tumour radio-respon-
siveness is still lacking. However, studies like the normal
tissue radiation toxicity (RAPPER) study, might allow an
increase in tumour dose for radiation-tolerant patients,
increasing their probability of local recurrence-free
survival. Furthermore, if a relationship exists between
tumour and normal tissue radiosensitivity, this will
further enhance the potential of genetic profiling in the
management of radiotherapy patients.
Application to archived samples
Many hospitals have extensive archives of formalin
fixed tumour and normal tissue material for which the
patient outcome is known. Theoretically, this resource
should be amenable to genomic, RNA and proteomic
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analysis, providing the opportunity for the identification
of key pathways involved in the radiation response of
tumour and normal tissue to clinically relevant irradia-
tion schedules. To date, the number of studies using this
material is rather limited, mainly because of the
difficulties of analysing samples containing very small
amounts of heavily degraded DNA.
However, methods have been developed for profiling
of SNPs in DNA from paraffin-embedded tissue [44, 45].
The problem of sample size has been addressed by using
whole gene amplification techniques and can be used to
detect changes in gene copy number [45]. Bead arrays
have also been used as a novel, high throughput method
for determining DNA methylation and gene silencing.
Changes in gene expression at the RNA level can also
be determined in paraffin-embedded sections using real
time PCR combined with proteinase digestion, and
further enhanced by laser-assisted microdissection to
focus on regions of interest and maximise the amount of
message in the sample [47].
Protein analysis can also yield information from
archival material [48]. Immunohisytochemical staining
of tissue sections with specific antibodies can be
successful if combined with pre-treatment using anti-
body retrieval methods, such as heating. This approach
can also be used to extract proteins from fixed material in
a manner that is suitable for 2D gel electrophoresis.
Alternatively, removal of paraffin from sections and
enzyme digestion have improved the effectiveness of
matrix-assisted laser desorption/ionisation liquid chro-
matography/mass spectrometry analysis. Protein inter-
actions are fundamental to the activation of pathways in
response to cytotoxic insults including radiation. These
interactions can be identified using a system that exploits
proximity ligation of oligonucleotides that are attached
to specific antibodies [49, 50].
This kind of information obtained using gene expres-
sion and proteomic approaches [51] has made it
increasingly possible to identify regulation of specific
pathways with radiotherapy outcome. This offers the
real possibility of using that knowledge to inform patient
care in the form of personalised therapy at the molecular
level. The contribution that proteomics, including mass
spectrometry could make in translating cell biology into
clinical practice is discussed in a recent review [52].
Biomarkers and functional imaging
In many respects, the holy grail of personalised
treatment planning is to use non-invasive functional
imaging technology to achieve ‘‘biologically conformal
treatment’’ [24]. This will require the integration of
reliable biomarkers with functional imaging using PET
or MRI. While we are a long way from being able to
detect levels of expression of genes or their products
using remote imaging methods in vivo, diffusion-
weighted MRI (DCE-MRI) has been used successfully
as a predictor of the response of brain, and colorectal
tumours, while [18F]FDG-PET data was of prognostic
value in lung, gastric, oesophageal, liver, breast, head
and neck, and cervical cancer (see Harry et al [53] for
recent review).
However, currently, the evidence that either biomar-
kers or functional imaging are superior to anatomical
imaging using CT in patient management is not
compelling, at least for head and neck cancer [54].
Molecular techniques are facilitating a rapid expansion
in our understanding of the signalling pathways that
regulate the radiation response of normal and malignant
cells. In parallel, advances in imaging technology,
particularly in MRI and PET, are increasing the range
of functional markers that can be quantified in tissues in
real time.
However, there is still some way to go before non-
invasive assessment of an individual patient’s tumour,
based on molecular markers for specific pathways, will
be possible. A few years ago, the mathematical complex-
ity of combining a large number of parameters in each
cell with different levels of expression according to each
unique position within a tumour and also the problem of
temporal changes during protracted treatments would
have been beyond the computational power available.
Enormous computing power can now be brought to bear
on the problem and, combined with advanced computa-
tional techniques, offers some expectation of success.
However, complex algorithms are only as good as the
inputs entered into them and we still face difficulties in
assigning weights to the multiple parameters that would
be needed, even if they can be measured accurately. For
example, epigenetic effects due to concomitant vascular
or immunological pathologies may override the predic-
tions of purely genetic characterisations.
Clearly, it will be many years before a fully integrated
approach to personalised treatment can be introduced to
clinical practice. In the meantime, though, elements of
this concept could contribute to treatment planning in
the near future.
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